ArticleBriefings in bioinformatics2026
Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Burden of Diabetic Kidney Disease at Global, Regional, and National Levels From 1990 to 2021].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diabetic complications are a major cause of disability and mortality among patients, and early identification of high-risk individuals is essential for precision prevention and management. In recent years, the rapid advancement of artificial intelligence (AI) has provided transformative tools for risk prediction and clinical decision support in diabetes care. In this narrative review, we systematically surveyed studies published between January 2015 and June 2025 in PubMed, Web of Science, and Scopus that applied AI-based predictive modeling for three major diabetic complications: diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic cardiovascular disease (CVD). A total of 58 studies were included, encompassing models based on clinical features, molecular omics, medical imaging, and multimodal data integration. Cross-scale and multimodal data fusion has emerged as a promising new paradigm, demonstrating improved predictive performance over single-modality approaches in three major diabetic complications. We also summarize the evolution from traditional machine learning to deep learning and, more recently, to large language models and agent-based systems, comparing their methodological characteristics, strengths, and suitable application scenarios. Finally, we proposed an actionable six-step framework and clinical translation pathway for AI in diabetic complications, outlining key steps from data curation and model development to validation, regulatory compliance, and real-world implementation. Together, these insights provide a roadmap toward developing robust, transparent, and clinically deployable AI systems capable of transforming the prevention and management of diabetic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.